UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1067-13
Program Prior Authorization/Notification
Medication Nexavar® (sorafenib tosylate)
P&T Approval Date 8/2008, 6/2009, 6/2010, 9/2010, 12/2010, 7/2011, 8/2012, 7/2013,
8/2014, 8/2015, 8/2016, 7/2017, 7/2018, 9/2019, 9/2020, 9/2021,
9/2022, 9/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Nexavar® (sorafenib tosylate) is a kinase inhibitor indicated for the treatment of unresectable
hepatocellular carcinoma, advanced renal cell carcinoma and locally recurrent or metastatic,
progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
The National Comprehensive Cancer Network also recommends the use of Nexavar for the
treatment of gastrointestinal stromal tumor (GIST), chordoma, osteosarcoma, acute myeloid
leukemia (AML), soft tissue sarcoma, salivary gland tumors, ovarian/fallopian tube
cancer/primary peritoneal cancer, and myeloid/lymphoid neoplasms with tyrosine kinase gene
fusions.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Nexavar will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Renal Cell Carcinoma (RCC)
1. Initial Authorization
a. Nexavar will be approved based on both of the following criteria:
(1) Diagnosis of renal cell carcinoma (RCC)
© 2024 UnitedHealthcare Services, Inc.
1
-AND-
(2) One of the following:
(a) Disease has relapsed
-OR-
(b) Both of the following:
i. Medically or surgically unresectable tumor
ii. Diagnosis of Stage IV disease
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
C. Hepatocellular Carcinoma
1. Initial Authorization
a. Nexavar will be approved based on both of the following criteria:
(1) Diagnosis of hepatocellular carcinoma
-AND-
(2) One of the following:
(a) Patient has metastatic disease
-OR-
(b) Patient has extensive liver tumor burden
-OR-
(c) Patient is inoperable by performance status or comorbidity (local
disease or local disease with minimal extrahepatic disease only)
-OR-
(d) Both of the following:
© 2024 UnitedHealthcare Services, Inc.
2
i. Patient is not a transplant candidate
ii. Disease is unresectable
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
D. Thyroid Cancer
1. Initial Authorization
a. Nexavar will be approved based on one of the following criteria:
(1) All of the following:
(a) Diagnosis of one of the following:
i. Follicular carcinoma
ii. Oncocytic carcinoma
iii. Papillary carcinoma
-AND-
(b) One of the following:
i. Unresectable recurrent disease
ii. Persistent locoregional disease
iii. Metastatic disease
-AND-
(c) One of the following:
i. Patient has symptomatic disease
ii. Patient has progressive disease
-AND-
(d) Disease is refractory to radioactive iodine treatment
-OR-
© 2024 UnitedHealthcare Services, Inc.
3
(2) All of the following:
(a) Diagnosis of medullary thyroid carcinoma
-AND-
(b) One of the following:
i. Disease is progressive
ii. Disease is symptomatic with distant metastases
-AND-
(c) History of failure, contraindication, or intolerance to one of the
following:
i. Caprelsa (vandetanib)
ii. Cometriq (cabozantinib)
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
E. Soft Tissue Sarcoma
1. Initial Authorization
a. Nexavar will be approved based on one of the following criteria:
(1) Diagnosis of angiosarcoma
-OR-
(2) Diagnosis of desmoid tumors / aggressive fibromatosis
-OR-
(3) Both of the following:
(a) Diagnosis of progressive gastrointestinal stromal tumors (GIST)
-AND-
© 2024 UnitedHealthcare Services, Inc.
4
(b) History of failure, contraindication, or intolerance to one of the following:
i. Gleevec (imatinib)
ii. Sutent (sunitinib)
iii. Stivarga (regorafenig)
iv. Qinlock (ripretinib)
-OR-
(4) Diagnosis of solitary fibrous tumor/hemangiopericytoma
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
F. Bone Cancer
1. Initial Authorization
a. Nexavar will be approved based on the following criteria:
(1) Both of the following:
(a) Diagnosis of chordoma
-AND-
(b) Disease is recurrent
-OR-
(2) Both of the following
(a) One of the following:
i. Diagnosis of osteosarcoma
ii. Diagnosis of dedifferentiated chondrosarcoma
ii. Diagnosis of high-grade undifferentiated pleomorphic sarcoma (UPS)
-AND-
(b) Not used as first-line therapy
© 2024 UnitedHealthcare Services, Inc.
5
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
G. Acute Myeloid Leukemia
1. Initial Authorization
a. Nexavar will be approved based on all of the following criteria:
(1) Diagnosis of acute myeloid leukemia (AML)
-AND-
(2) Patient has FLT3-ITD mutation-positive disease
-AND-
(3) One of the following:
(a) Patient has relapsed disease
(b) Patient has refractory disease
-AND-
(4) Used in combination with one of the following:
(a) Vidaza (azacitidine)
(b) Dacogen (decitabine)
-AND-
(5) Patient is unable to tolerate more aggressive treatment regimens
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
© 2024 UnitedHealthcare Services, Inc.
6
Authorization will be issued for 12 months.
H. Ovarian Cancer
1. Initial Authorization
a. Nexavar will be approved based on all of the following criteria:
(1) Diagnosis of one of the following:
(a) Ovarian cancer
(b) Fallopian tube cancer
(c) Primary peritoneal cancer
-AND-
(2) One of the following:
(a) Patient has persistent disease
(b) Patient has recurrent disease
-AND-
(3) Disease is platinum-resistant
-AND-
(4) Used in combination with topotecan
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
I. Salivary Gland Tumor
1. Initial Authorization
a. Nexavar will be approved based on all of the following criteria:
(1) Diagnosis of salivary gland tumor
-AND-
© 2024 UnitedHealthcare Services, Inc.
7
(2) Disease is one of the following:
(a) Recurrent and unresectable
(b) Metastatic
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
J. Myeloid/Lymphoid Neoplasms
1. Initial Authorization
a. Nexavar will be approved based on all of the following criteria:
(1) Diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FLT3
rearrangement
Authorization will be issued for 12 months.
2. Reauthorization
a. Nexavar will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Nexavar
therapy
Authorization will be issued for 12 months.
K. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B.
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
8
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim
logic. Use of automated approval and re-approval processes varies by program and/or
therapeutic class.
• Supply limit may be in place.
4. References:
1. Nexavar [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; August 2023.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
www.nccn.org . Accessed July 28, 2024.
Program Prior Authorization/Notification - Nexavar (sorafenib tosylate)
Change Control
8/2014 Annual review with changes to Coverage Criteria for hepatocellular
carcinoma, GIST and Thyroid Cancer. Updated formatting, Background
and References.
9/2014 Administrative change - Tried/Failed exemption for State of New Jersey
removed.
8/2015 Annual review. Updated thyroid cancer and osteosarcoma criteria.
Moved GIST criteria under soft tissue sarcoma. Added AML criteria.
Increased authorization and reauthorization from 6 months to 12
months for all indications. Updated background and references.
7/2016 Annual review. Revised criteria for renal cell cancer. Updated
references.
7/2017 Annual review. Updated background and criteria for the following
bone cancers; chordoma, dedifferentiated chondorosarcoma, and high-
grade undifferentiated pleomorphic sarcoma (UPS) per NCCN
guidelines. Updated references.
7/2018 Annual review. Updated background and added criteria for solitary
fibrous tumor/hemangiopericytoma. Updated references.
9/2019 Annual review. Updated background and added criteria for platinum-
resistant ovarian cancer. Updated references. Added general NCCN
recommended review criteria.
9/2020 Annual review with no changes to clinical coverage criteria. Updated
references.
9/2021 Annual review with no changes to coverage criteria. Updated
references.
9/2022 Annual review. Added criteria for salivary gland tumors and
myeloid/lymphoid neoplasms. Added state mandate disclaimer and
updated references.
9/2023 Replaced Hürthle cell with Oncocytic within Thyroid Cancer coverage
criteria. Added Qinlock to NCCN recommended first-line therapies for
© 2024 UnitedHealthcare Services, Inc.
9
GIST. Updated background and references.
9/2024 Annual review with no changes. Updated references.
© 2024 UnitedHealthcare Services, Inc.
10